GlassScriptPhysician profile
Elie Chalhoub
NPI 1336451665
$8,066.31
in general payments reported to CMS, 2019-2025
68 companies · $4,632 in 2025
The $4,632 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.92 · 2022: $26.64 · 2023: $686 · 2024: $2,710 · 2025: $4,632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,252 · Consulting Fee: $1,760 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,251.76 |
| Consulting Fee | $1,760.00 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Global Services, LLC | $1,760.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $558.35 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $475.72 | 2023-2025 | Enhertu, Imfinzi, Lynparza |
| Pfizer INC. | $297.32 | 2024-2025 | |
| Daiichi Sankyo INC. | $280.91 | 2024-2025 | Enhertu, Injectafer |
| E.R. Squibb & Sons, L.L.C. | $241.80 | 2022-2025 | Opdivo, Opdualag |
| Janssen Biotech, INC. | $217.30 | 2023-2025 | Tecvayli, Darzalex, Carvykti |
| Eisai INC. | $191.55 | 2023-2025 | |
| Apellis Pharmaceuticals, INC. | $149.90 | 2023-2025 | Empaveli |
| Emd Serono, INC. | $148.26 | 2023-2025 | Bavencio |
| Deciphera Pharmaceuticals INC. | $146.42 | 2023-2025 | Qinlock |
| Glaxosmithkline, LLC. | $143.38 | 2023-2025 | Jemperli, Zejula, Ojjaara |
| Gilead Sciences, INC. | $138.83 | 2021-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $133.81 | 2024-2025 | Iclusig, Fruzaqla, Alunbrig |
| Aveo Pharmaceuticals, INC. | $133.09 | 2024-2025 |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $129.85 | 2023-2025 | |
| Celgene Corporation | $128.35 | 2023-2025 | Pomalyst, Reblozyl, Breyanzi |
| Servier Pharmaceuticals LLC | $124.43 | 2023-2025 | |
| Genentech USA, INC. | $114.14 | 2023-2025 | Polivy, Columvi, Lunsumio |
| Ipsen Biopharmaceuticals, INC | $110.88 | 2024-2025 | Onivyde, Tazverik |
| Tersera Therapeutics LLC | $110.81 | 2024-2025 | Zoladex, Xermelo |
| Exelixis INC. | $109.47 | 2023-2025 | Cabometyx |
| Pharmacosmos Therapeutics INC. | $102.65 | 2024-2025 | Monoferric, Cosela |
| Genmab U.S., INC. | $98.47 | 2024-2025 | Tivdak, Epkinly |
| Adc Therapeutics America, INC. | $94.15 | 2024-2025 | |
| Stemline Therapeutics INC. | $91.26 | 2024-2025 | Orserdu |
| Merck Sharp & Dohme LLC | $90.92 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Spectrum Pharmaceuticals INC. | $90.62 | 2024-2025 | Rolvedon |
| Alexion Pharmaceuticals, INC. | $86.76 | 2023-2024 | Ultomiris |
| Abbvie INC. | $85.71 | 2024-2025 | |
| Array Biopharma INC | $80.58 | 2024-2025 | Mektovi, Braftovi, Lorbrena |
| Kyowa Kirin, INC. | $78.68 | 2024-2025 | Poteligeo |
| Jazz Pharmaceuticals INC. | $76.23 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $75.95 | 2024-2025 | Orgovyx |
| Blue Earth Diagnostics | $62.75 | 2023-2025 | Posluma |
| Bayer Healthcare Pharmaceuticals INC. | $56.52 | 2024-2025 | |
| Rigel Pharmaceuticals, INC. | $55.71 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| Astellas Pharma US INC | $55.60 | 2023-2025 | Xtandi, Vyloy |
| Lilly USA, LLC | $53.42 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Regeneron Healthcare Solutions, INC. | $50.37 | 2024 | Libtayo |
| Mirati Therapeutics, INC. | $49.85 | 2024 | Krazati |
| Adaptive Biotechnologies Corporation | $48.97 | 2024-2025 | Clonoseq |
| Incyte Corporation | $47.52 | 2024 | Monjuvi |
| Acrotech Biopharma INC. | $46.91 | 2024-2025 | Beleodaq |
| Dendreon Pharmaceuticals LLC | $43.82 | 2023-2024 | Provenge |
| Octapharma USA, INC. | $42.58 | 2025 | Octagam Immune Globulin (Human) |
| Coherus Oncology, INC. | $40.45 | 2024-2025 | Udenyca |
| Avyxa Pharma, LLC | $37.89 | 2025 | |
| Syndax Pharmaceuticals, INC. | $35.69 | 2025 | |
| Amgen INC. | $34.20 | 2023 | Kyprolis, Blincyto |
| Seagen INC. | $33.09 | 2023 | Padcev |
| Blueprint Medicines Corporation | $33.07 | 2023-2024 | Ayvakit |
| Tempus Ai, INC | $27.88 | 2025 | Xt Cdx |
| Azurity Pharmaceuticals, INC. | $27.31 | 2025 | Danziten |
| Myriad Genetic Laboratories, INC. | $25.63 | 2025 | Myrisk |
| Legend Biotech USA INC. | $25.14 | 2025 | Carvykti |
| Geron Corporation | $24.56 | 2025 | Rytelo |
| Recordati_rare_diseases_inc. | $24.52 | 2025 | Enjaymo |
| Pharmaessentia USA Corporation | $23.07 | 2025 | Besremi |
| Caris Mpi, INC. | $21.33 | 2025 | Mi Cancer Seek |
| Immunocore Limited | $21.19 | 2025 | Kimmtrak |
| Sobi, INC | $21.00 | 2025 | |
| Secura Bio, INC. | $20.50 | 2025 | Copiktra |
| Foundation Medicine, INC. | $17.19 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.12 | 2025 | |
| Janssen Pharmaceuticals, INC | $15.99 | 2025 | |
| Springworks Therapeutics, INC. | $15.59 | 2025 | Ogsiveo |
| G1 Therapeutics, INC. | $14.33 | 2023 | Cosela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elie Chalhoub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.